Lataa...
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
The US Food and Drug Administration (FDA) recently approved lorcaserin and the combination of phentermine and extended release topiramate (phentermine/topiramate ER) for the treatment of obesity in conjunction with a lifestyle intervention, expanding the therapeutic options for long-term obesity pha...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3926768/ https://ncbi.nlm.nih.gov/pubmed/24550678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S38979 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|